Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) classified as an antineoplastic agent and presented as an oral tablet for systemic use. It is indicated for the treatment of multiple myeloma and for certain myelodysplastic syndromes in adult patients, where it modulates immune response and inhibits malignant cell proliferation.

GNH USA supplies Lenalidomide Grindeks as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, providing the product to hospitals, oncology centres, transplant units, pharmacies and clinics worldwide under controlled quality standards.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma cells and dysplastic clones. - Multiple myeloma: improves progression‑free survival and overall response when used in combination regimens. - Myelodysplastic syndromes with del(5q): induces transfusion independence and cytogenetic remission. - Relapsed or refractory plasma cell disorders: provides disease control in patients who have failed prior therapies. - High‑risk smoldering multiple myeloma: delays progression to symptomatic disease.

Lenalidomide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require hydration. - Nausea: feeling of sickness often preceding vomiting. - Rash: mild skin eruptions or itching. - Constipation: difficulty passing stools. - Peripheral edema: swelling of lower extremities.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count increasing infection risk. - Severe thrombocytopenia: low platelet levels leading to bleeding. - Secondary primary malignancies: emergence of new cancers. - Hepatotoxicity: significant liver enzyme elevation or injury.

When prescribing Lenalidomide, clinicians should observe several safety precautions to minimize risk. - Pregnancy avoidance: drug is contraindicated in pregnancy (Category X) and requires effective contraception. - Thromboembolism prophylaxis: assess risk and consider anticoagulation in high‑risk patients. - Hematologic monitoring: regular CBC checks for neutropenia and thrombocytopenia. - Renal function assessment: dose adjustments may be needed in impaired renal clearance. - Infection vigilance: monitor for signs of infection due to immunosuppression. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Lenalidomide interacts with several medicines; awareness of these interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding when combined with lenalidomide‑induced thrombocytopenia.

Moderate Interactions (Monitor Closely): - P‑glycoprotein substrates (e.g., digoxin): potential alteration of plasma levels. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Vaccines (live attenuated): reduced efficacy; avoid during treatment. - NSAIDs: may increase risk of renal impairment when combined.